Open AccessEarly, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy
Author(s) -
Willemijn A.K.M. Windt,
Atsua Tahara,
Alex C. A. Kluppel,
Dick de Zeeuw,
Robert H. Henning,
Richard P.E. van Dokkum
Publication year - 2006
Publication title -
jraas. journal of the renin-angiotensin-aldosterone system/journal of the renin-angiotensin-aldosterone system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 46
eISSN - 1752-8976
pISSN - 1470-3203
DOI - 10.3317/jraas.2006.041
Subject(s) - glomerulosclerosis , medicine , focal segmental glomerulosclerosis , proteinuria , nephrectomy , urology , endocrinology , antagonist , vasopressin receptor , kidney , receptor
Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure. To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I).